纤维蛋白凝块特性可独立预测急性冠脉综合征不良结局:PLATO子研究
该研究基于PLATO试验中4354例急性冠脉综合征患者出院时的血浆样本,采用浊度法检测凝块溶解时间和最大浊度。经心血管危险因素校正后,溶解时间每增加50%与心血管死亡/自发性心肌梗死及心血管死亡风险升高相关;进一步校正其他预后生物标志物后,溶解时间与心血管死亡的关联仍显著。两种凝块特性均与主要出血事件无关。
要点
- 纤维蛋白凝块溶解时间延长独立预测ACS患者心血管死亡和自发性心肌梗死。
- 溶解时间与心血管死亡的关联在调整多种预后生物标志物后仍显著。
- 凝块特性与主要出血事件无关,不受随机抗血小板治疗影响。
核心结论
- 抗溶解的纤维蛋白凝块可独立预测ACS患者的不良结局。
- 靶向纤维蛋白凝块特性的新疗法可能成为改善ACS预后的新途径。
研究设计与样本
- PLATO试验子研究,收集4354例ACS患者出院时血浆样本,随机接受氯吡格雷或替格瑞洛治疗。
- 采用经验证的浊度法检测血浆凝块溶解时间和最大浊度(凝块密度指标)。
主要发现
- 校正心血管危险因素后,溶解时间每增加50%与心血管死亡/自发性心肌梗死相关(HR 1.17,95%CI 1.05-1.31;P<0.01),与心血管死亡单独相关(HR 1.36,95%CI 1.17-1.59;P<0.001)。
- 最大浊度每增加50%与心血管死亡风险升高相关(HR 1.24,95%CI 1.03-1.50;P=0.024)。
- 进一步校正白细胞计数、高敏C反应蛋白、高敏肌钙蛋白T、胱抑素C、N末端B型利钠肽原和生长分化因子-15后,溶解时间与心血管死亡的关联仍显著(HR 1.2,95%CI 1.01-1.42;P=0.042),最大浊度则不显著。
- 上述关联与随机抗血小板治疗无关(所有交互作用P>0.05)。
- 溶解时间和最大浊度均与主要出血事件无关。
临床怎么用
- 对于ACS患者,出院时检测纤维蛋白凝块溶解时间可能有助于识别心血管死亡和自发性心肌梗死高风险个体。
- 凝块特性与出血风险无关,可能为独立于出血风险的预后评估提供补充信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To determine whether fibrin clot properties are associated with clinical outcomes following acute coronary syndrome (ACS). METHODS AND RESULTS: Plasma samples were collected at hospital discharge from 4354 ACS patients randomized to clopidogrel or ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. A validated turbidimetric assay was employed to study plasma clot lysis time and maximum turbidity (a measure of clot density). One-year rates of cardiovascular (CV) death, spontaneous myocardial infarction (MI) and PLATO-defined major bleeding events were assessed after sample collection. Hazard ratios (HRs) were estimated using Cox proportional hazards models. After adjusting for CV risk factors, each 50% increase in lysis time was associated with CV death/spontaneous MI [HR 1.17, 95% confidence interval (CI) 1.05-1.31; P < 0.01] and CV death alone (HR 1.36, 95% CI 1.17-1.59; P < 0.001). Similarly, each 50% increase in maximum turbidity was associated with increased risk of CV death (HR 1.24, 95% CI 1.03-1.50; P = 0.024). After adjustment for other prognostic biomarkers (leukocyte count, high-sensitivity C-reactive protein, high-sensitivity troponin T, cystatin C, N-terminal pro B-type natriuretic peptide, and growth differentiation factor-15), the association with CV death remained significant for lysis time (HR 1.2, 95% CI 1.01-1.42; P = 0.042) but not for maximum turbidity. These associations were consistent regardless of randomized antiplatelet treatment (all interaction P > 0.05). Neither lysis time nor maximum turbidity was associated with major bleeding events. CONCLUSION: Fibrin clots that are resistant to lysis independently predict adverse outcome in ACS patients. Novel therapies targeting fibrin clot properties might be a new avenue for improving prognosis in patients with ACS.
引用
- Sumaya W, Wallentin L, James SK, et al. Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. Eur Heart J. 2018. PMID: 29390064. doi:10.1093/eurheartj/ehy013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。